Alopecia Induced by CDK 4/6 Inhibitors and Its Impact on the Quality of Life of Patients with Advanced Breast Cancer

This study investigates the impact of alopecia induced by CDK 4/6 inhibitors on the quality of life in 51 female breast cancer patients in the MENA region. Nearly half of the participants experienced alopecia, with 26% at CTCAE grade I and 23% at grade II. The study found that higher alopecia severity significantly worsened quality of life, particularly in emotional, symptomatic, and functional aspects, as measured by the Hair-Specific Skindex-29 questionnaire. Both the severity of alopecia and the specific CDK4/6 inhibitor used were significant predictors of quality-of-life impairment.